Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies. In the last decade alone, immunotherapies, targeted therapies, antibody-drug conjugates and radiopharmaceuticals have become standard treatment for a variety of tumors.
Yet none are silver bullets, leaving room for young companies testing out new ideas, like Delphia Therapeutics, which launched on Thursday with $67 million in funding.
“To get a different outcome for patients requires a different approach,” said Delphia co-founder and CEO Kevin Marks.
